Scarlet has assembled a range of technologies in order to help it achieve its aims.
- Production of highly universal red blood cells (RBCs) in the lab from immortalised cell lines.
- Genetic manipulation of the cell lines in order to create RBCs with enhanced properties (due to the presence of additional therapeutic proteins – tRBCs).
- Technologies for the maintenance of the additional therapeutic proteins within the RBCs
- The ability to generate RBC producing cell lines that can then be further manipulated to provide more complex treatments and to be compatible with a higher percentage of patients.
Production of tRBCs from RBC producing cell line
The generation of RBCs from cell lines rather than from donated cells, as is done by our competitors, has very significant advantages including:
- “biologic-like” manufacturing process allowing a scalable and reproducible process
- Ability to generate highly universal RBCs that can treat the vast majority of patients rather than having to match blood types of donors and patients
- Ability for more complex manipulation of the RBC to generate a broader range of products and optimise the activity, and therefore efficacy and safety of those products